‘Otezula,’ psoriasis therapy, acquires approval from MFDS
Celgene Korea(CEO Tae-Jin Ham) announced ‘Otezla(generic name: apremilast),’ an oral selective phosphodiesterase-4(PDE-4) inhibitor, acquired approval from the Ministry of Food and Drug Safety on the 20 November and the company is planning to launch it with the national health insurance benefits....
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
